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Abstract
Background: The database of a major regional health insurer was employed to identify the number and frequency
of covered patients with chronic kidney disease (CKD). We then examined the characteristics of their care as
defined, in part, by the frequency of physician visits and specialty referral, the characteristics of laboratory testing
and total costs as indices of the quality of care of the subject population.
Methods: This retrospective, cross-sectional study analyzed insurance claims, laboratory results and medication
prescription data. Patients with two estimated glomerular filtration rate readings below 60 ml/min/1.73 m2 (n = 20,388)
were identified and classified by CKD stage.
Results: The prevalence of CKD stages 3a and above was 12 %. Vascular comorbidities were common with prevalence
increasing steadily from stage 3a through stage 5. Only 55.6 % of stage 4 CKD patients had claims for nephrology visits
within one year of their index date. Fifty-nine percent of patients had claims for renin-angiotensin system (RAS) blockers.
Twenty-five percent of patients in stage 3a CKD filled a prescription for non-steroidal anti-inflammatory drugs. Fifty-two
percent of patients who developed end-stage renal disease received their first dialysis treatment as inpatients.
Conclusions: The pattern of medical practice observed highlights apparent deficiencies in the care of CKD patients
including inappropriate medication use, delayed nephrology referral, and a lack of preparation for dialysis. This study
shows the potential value of using large patient databases available through insurers to assess and likely improve
regional CKD care.
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Background
Chronic kidney disease (CKD) is a major public health
problem that is associated with increased morbidity,
mortality, and healthcare costs for both individual pa-
tients and health care systems [1–3]. The health burden
caused by CKD is likely to grow sharply over the next
several years due to an increasing elderly population and
the escalating prevalence of comorbid conditions such
as type II diabetes. Indeed, the United States Renal Data
System (USRDS) reported a 104 % increase in the preva-
lence of end-stage renal disease (ESRD) between 1990
and 2002 [4, 5]. Therefore, it is crucial to monitor the
population at risk.
Mining high-dimensional insurance claim data can yield
population-level insights on epidemiology, outcomes and
economics of a particular disease entity [6, 7]. Quality data
of the sort provided during the processing of health insur-
ance claims could offer a unique window into CKD preva-
lence, treatment modalities, and outcomes. Diagnostic
testing rates, prevalence of comorbidities, and manage-
ment strategies relating to CKD have yet to be described
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for the Albany and Buffalo metropolitan areas of New
York. Consequently, we analyzed the insurance claims for
more than one million individuals residing primarily in
these areas to assess the regional recognition and care of
CKD patients.
The agenda of many Federal funding agencies such as
the Patient Centered Outcomes Research Institute
(PCORI) is to determine best practice for using observa-
tional data in clinical research. This study provides im-
portant quality data for the care of chronic kidney disease.
Studies applied to observational data have the disadvan-
tages of lacking both randomization and structure in the
data collection process. Nonetheless, they are truly in vivo
studies where the practice settings are representative of
reality. They also have the advantage that the number of
patients included in the trial is often larger: this affords
the observational study increased power to identify im-
portant clinical outcomes.
Methods
Study design and sample
The study population for this report was derived from a
large database of health insurance claims records from a
major insurer serving the greater Metropolitan Buffalo
and Albany regions of New York State. These data were
gathered between January 2007 and August 2013. Data
collection was initiated by the University at Buffalo
School of Medicine and Biomedical Sciences. Use of the
data for analysis and interpretation was approved by the
institutional review board of the School of Medicine of
the State University of New York at Buffalo. All of the
authors of this manuscript were HIPPA certified. Since
all data was de-identified individual informed consent
was not obtained. Original data for this manuscript
resides in the Institute for Health Information of the
School of Medicine and Biomedical Sciences. Access to
this date is restricted to only the investigators.
The database did not contain information for sub-
scribers for whom the insurer had not received claims;
therefore, every patient (n = 1,189,068) had at least one in-
surance claim. Of these individuals, only 168,506 patients
had all of the data necessary to identify medications and
laboratory results required for our analysis of that group.
Patients with eGFR readings below 60 ml/min/1.73 m2 on
two occasions at least 90 days apart (n = 20,388) were clas-
sified by CKD stage (Fig. 1).
Patients were assigned index dates set at the date of
their second abnormal eGFR reading. Each patient was
also assigned a unique identification number that
allowed patient data to be aggregated across all claim
types (pharmacy, professional, inpatient, outpatient, and
laboratory), all of which were stored in separate database
tables.
Baseline data identification and collection
We used the standard coding tools to extract informa-
tion from the data set, including Current Procedures
and Terminology (CPT); International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-
9CM); Logical Observation Identifiers Names and Codes
Fig. 1 Flowchart of the study population
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(LOINC); National Provider Identification (NPI); and
National Drug Codes (NDC).
We utilized Computer Task Group’s HIE Lite platform
to aggregate data from several disparate data sources
including medical claims, laboratory results, pharmaceut-
ical claims, and patient demographics. After normalization
of the dataset we were able to develop new models to
examine the temporal aspects of disease progression and
identify the critical gaps in care and most significant
medical events.
Prevalence rates for select comorbid conditions
ICD-9CM diagnosis codes were classified according to the
Agency for Healthcare Research and Quality’s Clinical
Classification Software categories for coronary artery
disease (CAD), congestive heart failure (CHF), peripheral
vascular disease, cerebrovascular accidents (CVA), chronic
obstructive pulmonary disease (COPD), malignancy,
hypertension, diabetes mellitus, and mental illness. Co-
morbid conditions were considered “present” in a patient
if there was at least one qualifying diagnosis code in their
record.
CKD prevalence
CKD was defined according to National Kidney
Foundation–Kidney Disease Outcomes Quality Initia-
tive (NKF–KDOQI) guidelines by the recording of
two determinations separated by at least three months
of eGFRs of less than 60 ml/min/1.73 m2 using the Modi-
fication of Diet in Renal Disease equation. The prevalence
of CKD was calculated by dividing the number of patients
meeting the definition of CKD (n = 20,388) by the number
of patients who had two calculated eGFR and claims
records for medications and laboratory data (n = 168,506).
Laboratory data
Laboratory tests for iron profile (iron, total iron binding
capacity, and ferritin), albumin, albumin/creatinine ratio
(ACR), hemoglobin A1c (glycosylated hemoglobin), 25-
hydroxy Vitamin D3, phosphorus, calcium, intact parathy-
roid hormone (PTH), and lipid level results were identified
using LOINC and tracked throughout the observed period.
Prescription information
NDC numbers were used to identify medications that
corresponded with classes of interest. Specifically, renin-
angiotensin system (RAS) blockers, phosphate binders,
active Vitamin D analogs, erythropoesis-stimulating agents
(ESAs), anti-hyperlipidemic, and antihypertensive agents
were recorded at baseline and at the end of the study
period.
Renal “crash”
We defined renal crash patients were those who met all
of the following criteria: 1. developed ESRD during the
observed period; 2. experienced their initial dialysis in an
inpatient setting; 3. had at least two eGFR values indica-
tive of CKD (less than 60 ml/min/1.73 m2) before their
first dialysis; and 4 had dialysis claims persisting for
90 days after the initial dialysis billing (Fig. 1).
Statistical analysis
Data analysis consisted of using simple frequencies with
percentages to determine CKD prevalence, comorbid
condition prevalence, medication use, laboratory testing,
and nephrologist visits within the qualifying population.
Descriptive statistics such as mean, median, and standard
deviation were used for continuous variables. Pearson’s
Chi-square test was applied to find associations between
two categorical variables. Student’s t-test and Kruskal-
Wallis non-parametric ANOVA were used to determine
significant differences between average values across
groups. All calculations were performed using v3.1.0 of
the R language and environment for statistical computing.
Results
Population characteristics
CKD prevalence in the study population with the requis-
ite available lab data was 12 % (20,338 patients out of
the 168,506 patients with two or more eGFR readings).
Sixty- one per cent of the CKD patients were female.
Eighty-two percent of patients were over 60 years of age
and the median age was 72 years.
Comorbidities
The prevalence of comorbidities by CKD stage was evalu-
ated. Hypertension was present in 89.0 % of patients and
42.3 % had diabetes. Cardiovascular diseases such as CAD,
CVA, and CHF were common and their prevalence
increased from 20 % in CKD stage 3a to 35 % in CKD stage
5. Patients with CKD also exhibited a relatively high rate
(29.5 %) of non-dermatologic cancer diagnoses. The other
comorbidities commonly reported in CKD cohort were
depression (17 %), anxiety (15 %), other mental illnesses
(28 %), and substance abuse (3 %). In contrast to cardiovas-
cular complications, the rates of behavioral health condi-
tions and cancer did not rise substantively as CKD
progressed.
Provider encounters
Table 1 presents the annualized percentage of patients
who made at least one visit to a primary care physician
(PCP) or a nephrologist during the 12 months after their
first appearance in the data set.
Nephrologists saw 14.5 % of patients within one
year of their index date: 6.6 % in stage 3a, 21.7 % in
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stage 3b, 55.6 % stage 4, and 87.7 % in stage 5. The
mean eGFR at the time of first nephrology visit was
39.2 (+/− 15.54) ml/min/1.73 m2. The distribution of
eGFR values at the time of first nephrology claim is
presented in Fig. 2.
Screening and prevalence for associated conditions
Table 2 depicts the frequency with which testing recom-
mended for patients with CKD was performed.
Both screening for and prevalence of conditions as-
sociated with CKD varied widely depending on neph-
rology referral and CKD stage. Patients were more
likely to have had tests for metabolic bone disease
and anemia if they were seen by a nephrologist. Goal
achievement for selected labs prescribed by NKF–
KDOQI guidelines varied with CKD stage.
Prescribing patterns
The prescription claims for medications recommended
to be employed or avoided in patients with CKD are
depicted in Table 3.
Only 58.8 % of patients had claims for RAS blockers.
RAS blocker use was greater in early stages of disease and
in those seeing a nephrologist. The use of ESAs increased
from 0.4 to 17.3 % from stage 3a to stage 5. Use of phos-
phate binders, active Vitamin D analogs, and ESAs in-
creased with severity of CKD and with nephrology visits.
Twenty-five percent of patients in stage 3a CKD filled a
prescription for non-steroidal anti-inflammatory drugs
(NSAIDs). Even some patients in stage 5 were on pre-
scribed NSAIDs (5.9 %). Filled prescription rates for
NSAIDs were significantly lower in the collective CKD
population seen by nephrologists (19 vs. 24 %, P < 0.005).
There was, nonetheless, a substantial number of patients
Table 1 Annualized percentage of visits to PCP and nephrologist
CKD stage No. of patients Patients who saw either a PCP or nephrologist Patients who saw a PCP (%) Patients saw a nephrologist (%)
3a 13,648 9598 9443 (69.2) 628 (4.6)
3b 5178 3884 3705 (71.6) 865 (16.7)
4 1292 1069 966 (74.8) 575 (44.5)
5 220 204 183 (83.2) 15 (70.9)
All 20,338 14,755 14,297 (70.3) 2224 (10.9)
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Fig. 2 Distribution of eGFR values at first nephrology visit eGFR. Values (ml/min/1.73 m2)
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on prescribed NSAIDs even among those seen by
nephrologists.
Preparation for dialysis
Overall, 366 patients in the entire study population
(n = 168,506) started chronic dialysis for ESRD; of
these patients, 249 had documented CKD prior to the
initiation of dialysis. Only 26 % of these 249 patients
had an arteriovenous fistula when they first received
dialysis. The initial dialysis occurred in an inpatient
setting for 51.8 % of these patients. Sixty-three per-
cent of patients who “crashed” had claims for initial
nephrology visits more than one year prior to starting
dialysis, 13.9 % had claims between 90 days and one
year prior to dialysis, 10 % had claims less than
90 days prior, and 13.1 % had no nephrologist claims
before their crash [Table 4].
In the subgroup of patients who were found to have a
renal crash, those who saw a nephrologist in the last
year were compared with those who did not see a neph-
rologist. Crashes were less frequent when patients had
an encounter with a nephrologist in the last year (48 vs.
68 %, P < 0.005).
Discussion
In a selected group of 168,506 insured individuals who
had at least two qualifying eGFR readings separated by
two months and claims records for medications and la-
boratory studies, the prevalence of CKD stage 3 and
above was 12 % (20,388). The pattern of medical practice
Table 2 Frequency of laboratory tests
CKD related lab tests Percent of CKD patients who had lab test and did or did not see a nephrologist, by stage
Stage 3a Stage 3b Stage 4 Stage 5 All stages
(n = 13,648) (n = 5178) (n = 1292) (n = 220) (n = 20,338)
No Yes No Yes No Yes No Yes No Yes
Hemoglobin 84.9 % 92.8 % 85.3 % 93.9 % 83.6 % 95.3 % 92.9 % 89.3 % 85.0 % 93.5 %
Iron 15.7 % 34.1 % 19.6 % 42.6 % 20.4 % 55.1 % 33.7 % 41.3 % 16.6 % 41.4 %
Total iron binding capacity 12.8 % 31.3 % 4.4 % 39.9 % 0.6 % 53.5 % <0.01 % 39.8 % 13.6 % 38.8 %
Ferritin 13.8 % 30.7 % 17.7 % 38.2 % 15.6 % 51.9 % 21.4 % 38.8 % 14.7 % 37.6 %
Calcium 99.6 % 99.6 % 99.5 % 99.8 % 98.9 % 99.8 % 100.0 % 100.0 % 99.6 % 99.7 %
Phosphate 6.0 % 52.7 % 7.6 % 64.0 % 10.8 % 73.9 % 24.1 % 60.8 % 6.5 % 61.5 %
Vitamin D 47.2 % 54.4 % 42.6 % 56.3 % 36.8 % 54.9 % 21.4 % 35.4 % 45.9 % 54.5 %
PTH 6.5 % 35.8 % 8.3 % 51.9 % 10.6 % 64.2 % 7.1 % 49.0 % 7.0 % 47.5 %
Albumin 95.2 % 97.4 % 93.8 % 97.3 % 93.4 % 96.7 % 100.0 % 91.7 % 94.9 % 97.0 %
ACR 28.9 % 49.0 % 8.2 % 49.5 % 0.9 % 44.5 % <0.01 % 23.8 % 29.0 % 47.4 %
A1c 49.3 % 62.3 % 49.1 % 61.6 % 47.4 % 58.1 % 50.0 % 45.1 % 49.2 % 60.6 %
Abbreviation: A1c glycosylated hemoglobin, ACR albumin-creatinine ration, CKD chronic kidney disease, PTH parathyroid hormone
Table 3 Prescription drug usage in CKD patients
CKD-related
medication
CKD patients who took medication and did or did not see a nephrologsit (%), by stage
Stage3a Stage 3b Stage 4 Stage 5
No Yes No Yes No Yes No Yes
(n = 11,583) (n = 2065) (n = 3202) (n = 1976) (n = 378) (n = 914) (n = 14) (n = 206)
RAS blocker 6478 (55.9) 1390 (67.3) 1975 (61.7) 1312 (66.4) 204 (54.) 516 (56.5) 4 (28.6) 89 (43.2)
Aldosterone antagonist 440 (3.8) 252 (12.2) 210 (6.6) 276 (14.0) 33 (8.7) 111 (12.1) 1 (7.1) 5 (2.4)
Phosphate binder 4 (<0.1) 26 (1.3) 0 (0) 71 (3.6) 5 (1.3) 157 (17.2) 2 (14.3) 120 (58.3)
Vitamin D 588 (5.1) 256 (12.4) 113 (3.5) 291 (14.7) 15 (4.0) 272 (29.8) 1 (7.1) 78 (37.9)
PPI 3592 (31.0) 810 (39.2) 1087 (33.9) 812 (41.1) 140 (37.0) 394 (43.1) 3 (35.7) 85 (41.3)
ESA 10 (0.1) 39 (1.9) 15 (0.5) 88 (4.5) 6 (1.6) 123 (13.5) 0 (0) 38 (18.4)
Loop diuretics 2193 (18.9) 809 (39.2) 1029 (32.1) 958 (48.5) 147 (38.9) 572 (62.6) 4 (28.6) 99 (48.1)
Statin 6056 (52.3) 1249 (60.5) 1721 (53.7) 1197 (60.6) 179 (47.4) 539(59.0) 5 (35.7) 110 (5.4)
NSAID 2939 (25.4) 492 (23.8) 662 (20.7) 392 (19.8) 45 (11.9) 125 (13.7) 2 (14.3) 11 (5.3)
Abbreviations: CKD chronic kidney disease, ESA erythropoeisis-stimulating agent, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, RAS
renin-angiotensin system
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observed in this study suggests that substantial opportun-
ities exist to improve care for this population. Several find-
ings are noteworthy: first, the proportion of patients with
CKD who had claims for care by a nephrologist (24 %) was
smaller than expected, but increased with the severity of
CKD. The annualized percentage of patients who visited
nephrologists increased as kidney function worsened, yet
only 55.6 % of patients with stage 4 CKD had a claim from
a nephrologist. Second, the percentage of patients receiving
laboratory tests recommended by the NKF–KDOQI stand-
ard was low, even in those patients seen by a nephrologist.
Third, the level of prescription of RAS blockers was rela-
tively low, though higher when patient had a nephrology
claim (64.1 vs. 57.1 %, P < 0.005) and declined with advan-
cing CKD (stage 3, 60 %; stage 4, 55.7 %; stage 5, 42.3 %).
Fourth, a substantial number of patients in the more ad-
vanced stages of CKD (stages 4 and 5) were prescribed po-
tentially nephrotoxic NSAID medications. Finally, among
patients who developed ESRD, 51.8 % had their first in-
stance of dialysis as inpatients and only 26 % had evidence
that an arteriovenous fistula had been placed.
CKD patients had a high frequency of comorbidities
similar to what has been reported [8]. The higher rates of
various vascular comorbidities in CKD patients could be
related to a higher prevalence of diabetes, hypertension,
elevated triglycerides and low high-density lipoprotein
levels, increased oxidative stress, inflammation, physical
inactivity, anemia, vascular calcification, and left ventricu-
lar hypertrophy. Another important finding in the study is
the higher than expected prevalence of cancer in CKD pa-
tients. In a recent study Wong et al. identified moderate
CKD (stage 3) was identified as an independent risk factor
for the development of cancer among older men [9]. A
causal relationship between cancer and CKD has not been
established. It is possible, however, that CKD patients may
have a higher cancer rate related to decreased immune
surveillance; alternatively, patients with cancer may be
more prone to CKD due to unrecovered acute kidney in-
jury secondary to cancer itself and/or nephrotoxicity from
chemotherapy or other cancer treatments [9–12].
Improving management of CKD during its early stages
can reduce the growing burden of ESRD. Although there
are guidelines developed by medical experts that define
best practices for early-stage CKD management, their
implementation may not be optimal and result in poor
outcomes [4, 13–15]. Results from the NKF’s Kidney Early
Evaluation Program study revealed poor control of cardio-
vascular risk factors among CKD patients [8]. Appropri-
ately managing anemia, hypertension, and dyslipidemia
could also help prevent cardiovascular mortality, which is
a leading cause of death among CKD patients. In this
population, iron saturation tests were performed in only
23 % of patients with CKD and PTH levels were assessed
in only 49 % of patients in CKD stage 4. Although these
tests were performed more frequently when nephrologists
were involved in patient care (Table 3), testing rates still
fell short of guideline recommendations.
Interventions to slow progression are critical to the
effective treatment of CKD and prevention of ESRD. RAS
blockers have been shown to retard the progression of
kidney disease [16–19]. The American College of Phys-
ician (ACP) guidelines for CKD care recommend prescrib-
ing RAS blockers to every CKD patient unless
contraindicated [20]. Patients in this study who saw a
nephrologist were more likely to be prescribed RAS
blockers (4 vs. 57.1 %, P < 0.005). In a study of patients in
the greater metropolitan Boston, Massachusetts, area
more than 10 years ago, Kausz, et. al. reported that RAS
blockers were used in 49 % of patients when seen by a
nephrologist [21]. We found RAS blocker use was far
from the now even higher rate recommended for those
without contraindications but greater than that noted in
the 2000 Boston study [13–15]. There still may be room
for improvement: in Singapore for example, a more
Table 4 Timeframe of Nephrologist claims prior to crash
CKD patients who crashed (%) CKD patients who did not crashed (%)
(n = 129) (n = 120)
Initial claim:
More than i year prior to crash 81 (62.7) 79 (65.8)
90 days to 1 year prior to crash 18 (13.9) 27 (22.5)
Fewer than 90 days prior to crash 13 (10) 8 (6.7)
After first dialysis 17 (13.1) 6 (5)
Last claim:
More than i year prior to crash 6 (4.6) 4 (3.3)
90 days to 1 year prior to crash 14 (10.8) 4 (3.3)
Fewer than 90 days prior to crash 92 (71.3) 106 (88.3)
After first dialysis 17 (13.1) 6 (5)
Abbreviations: CKD chronic kidney disease
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controlled medical system, Ang et. al. found in 2011 that
84 % of CKD patients were prescribed RAS blockers [22].
It is clinically sound practice for CKD patients to avoid
nephrotoxic medications such as NSAIDs despite conflict-
ing study results linking these medications and kidney
disease progression [23–25]. In a study that employed
NHANES data, Plantinga, et. al. examined NSAID use
among CKD patients [23]. Using a questionnaire method,
they found that 5 % of patients with moderate to severe
CKD reported NSAID use. In this population NSAID use
was much higher from 25 % in stage 3a down to 5.9 % in
stage 5. When combined with RAS blockers, which are
commonly prescribed to elderly patients with hyperten-
sion, NSAIDs may increase the risk of superimposed acute
kidney injury. This point alone makes the level of contin-
ued NSAID prescription revealed by this study a topic of
concern. Clinicians may have felt that the presence of
comorbid conditions warranted the use of NSAIDs to
achieve better quality of life despite the inherent risks.
Although patients under nephrology care filled fewer
claims for NSAIDs than those seen by PCPs alone, any
NSAID prescription for a patient with advanced CKD
who is receiving nephrology care is worrisome. It is not
always possible from our database to identify a prescribing
practitioner’s specialty. Furthermore, because claims data
do not generally include over-the-counter medications,
our results likely underestimate NSAID use in the study
population.
Despite improvements in dialysis care and increased
spending on healthcare, the mortality rate among ESRD
patients remains high. Several factors, including delayed
referral to nephrologists, appear to influence mortality
among dialysis patients [26–31]. Late referrals reduce the
likelihood of treatment for anemia, dyslipidemia, renal
bone disease and the timely placement of appropriate vas-
cular access, preemptive kidney transplant, or informed
selection of dialysis modality. Indeed, earlier involvement
of the nephrologist was associated in one study with lower
subsequent patient mortality [28].
The NKF recommends that patients consult a nephrolo-
gist when their eGFR dips below 30 ml/min/1.73 m2. Late
nephrology referral is a widespread problem, as described
by Sprangers, et. al. who claim of up to 84 % of patients are
referred late [30]. The analysis of our data set shows that
23 % of patients had a late nephrology referral. Referral to
nephrology did not necessarily obviate “crashing” into dia-
lysis, since 50 % of patients who were seen by nephrologists
three months prior to dialysis received inpatient dialysis,
compared to 75 % who were not seen by a nephrologist in
three months. Indeed, 71 % had seen their nephrologist
within 90 days of the crash. We also found that 80 % of
patients who experienced a renal “crash” required a central
venous catheter as vascular access. Nonetheless, crashes
were less frequent when patients saw a nephrologist (48 vs.
68 %, P < 0.005). The reasons for urgent inpatient dialysis
and delayed or missing claims for nephrology, however,
could not be established in this study.
There are several limitations to this study, some of
which are inherent to using claims data in population
studies. We were unable to obtain data on patients’ race
from the provider. As per NKF–KDOQI guidelines, we
identified CKD using two values of serum creatinine,
taken three months apart. The definition of CKD for this
study was based on eGFR readings below 60 ml/min/
1.73 m2. As a result, it excluded patients with CKD
stages 1 and 2, which, according to NHANES data, con-
stituted about one-third of all patients with CKD [32].
The requisite laboratory data to establish the presence of
CKD was available on only about 15 % of the nearly 1.2
million insured individuals. Within that group the inci-
dence of CKD stages 3 or higher was 12 %. This is
higher than the 8 % reported by NHANES, but the dif-
ference could be explained by the fact that patients at
risk for CKD are more likely to have the relevant labora-
tory tests [2]. Indeed, the patients we studied were de-
fined based on criteria that included sufficient laboratory
testing to confirm CKD and could result in an appar-
ently higher prevalence.
Another limitation is that claims data, by its nature,
does not include information on uninsured patients and
our analyses may not be applicable to their care, which
may be less robust. The intention of this study, however,
was not to report on a representative cohort of the
population but rather to characterize the care received
by patients with clearly established CKD. One of our
study’s strengths is that we included all the claims from
a major regional insurance provider, as well as available
laboratory data, and did not limit to a specific group
alone. In the future, electronic health record data could
be added to the claims data to improve our ability to
surveil patient conditions and outcomes [32, 33]. Studies
applied to observational data typically lack both
randomization and structure in the data collection
process. They are, however, truly in vivo studies where
the practice settings are representative of reality and
often include a larger patient base.
Conclusions
In conclusion, we were able to document striking devia-
tions from the quality of care guidelines in terms of
nephrology referral timing, recommended medication
use, and the frequency with which chronic dialysis was
initiated in under- or unprepared patients. These find-
ings demonstrate that regional insurance claim data can
provide information useful to assess the prevalence and
treatment of CKD. The analyses of treatment patterns
presented in this study indicate times and settings where
better education, information sharing, and adherence to
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guidelines can make real improvements in CKD patient
care, particularly where nephrotoxic medications, spe-
cialist referral, and preparation for renal replacement
therapy are concerned. Future initiatives to consolidate
and enrich such efforts should become the hallmarks of
CKD care in Buffalo, Albany, and beyond.
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